代表其个人观点国胜证券研究人员的发言内容仅代表当日的判断具体请参见完整版的研究报告未经国胜证券事先书面许可任何机构或个人严禁录音、转发及相关解读涉嫌违反上述情形的我们将保留追究相关方法律责任的权利 各位投资者大家下午好我是国胜证券的药业研究商杨欢迎大家来参加我们国胜医药团队组织的线上策略会医药云端的酸奶加血糖鉴今天这一场是珍宝岛我们组织这个线上策略会其实也是在 现在整体市场比较低迷的状态下我们系统性的希望投资者可以跟上众公司做一些深度的交流系统性的多组织一些特色的公司跟大家做线上的这样的一个深度的沟通把它推出一些投资机会未来做准备那么这场是这么早我们也非常荣幸的请到了公司的两位领导财务总监王总和董秘张总两位领导最近跟大家做交流 下面我就把时间交给两位领导首先由两位领导给大家简单介绍一下公司的一些情况后面我们再开启问答大家可以准备问题后面等领导做完介绍之后大家可以按信息简介做提问那么辛苦两位领导了把时间交给你们好的 谢谢张老师 大家好,我是珍宝岛的罗蜜张东方然后我们参会的领导还有我们的财务总监王伟总因为在上个月的时候6月5号我们在北京组织了一次投资者活动所以当时我们的总经理也对公司的基本情况做了一个介绍 不知道 ...

非常感谢国盛组织这个会议现场各位投资者大家好我先和大家介绍一下我们上半年的一些情况就是在业务方面 首先呢就是我们从整体看吧我们在上半年的话是实现了我们年初就是来去预定的就是这个收入30利润有35左右的这样的一个增长水平那么上半年的话我们看基本上是符合预期的从单个季度来看的话我们一季度 是有40然后二级度的话也是在30以上的一个水平就是从那里看的话都还是非常不错还有就是我们上半年的整个的这个新店的这种新城的这种扩张都还是相比前两年的话速度其实是在加快的我们在上半年已经开了 应该有十三家吧十二家的一个冰店其中包括像新加坡然后还有这个新城像长沙就是这些地方那么我们核心还是围绕着一个现有城市的进一步加密尤其像上海和江浙地区 然后再就是这种新城的开拓那么我们全年的话预计是10到15家的一个新店那么从上半年情况看的话我们基本上那个开拓的目标其实就已经完成差不多了那么在下半年的话我们还是会有继续的会有新的门店有并购有自建的这种项目还是会持续出来 对那个我们上半年大概情况我先介绍到这吧然后后面看投资者有问题我们再互相聊一下啊好谢谢哎好的好的谢谢王总我这边就先提两个小问题吧第一个就是咱们呃六月份收购的这个湖南这边的医院的情况然 ...

Summary of Conference Call Company/Industry Involved - The conference call is related to Tianfang Securities, a financial services company Core Points and Arguments - The meeting was a closed-door session, emphasizing confidentiality and the prohibition of recording or distributing the meeting content without permission from Tianfang Securities [1] Other Important but Possibly Overlooked Content - Tianfang Securities reserves the right to pursue legal action against any parties that violate the confidentiality requirements set forth during the meeting [1]

更多资料加入知识星球:水木调研纪要 关注公众号:水木纪要 医药行业 2024 中期策略: 聚焦"改善"和"创新"20240703 摘要 国家医保局近期发布了一系列药品价格机制新政，旨在消除不同渠道间的价格差异，引。noi in4987 导企业合理制定价格。过此动缔变该动用息宣体日米立片吸め忙上一步对于过于"江苏" • 导企业合理制定价格。这些政策将对明显高价品类产生降价压力,龙头药店可以通过生 游利润获取或发展大健康品类来对冲风险,而小型药店则可能面临更大的经营压力,加 速行业整合与集中度提升。 调研 战 院外渠道在医药市场中扮演着重要角色,承担着及时供应常用药品、满足居民日常用药 需求的功能,并提供咨询服务。参考国内超市业态,龙头药店目前的净利率水平处于合 理水平,考虑到更高的人力成本和合规经营成本,未来净利率将保持稳定。 当前政策仍然坚持市场定价基本原则,对整体零售市场影响有限,但会加速行业集中度 • 提升。大型连锁药店在线上线下均具有竞争优势,线上 020 模式毛利率约为 20-25%, 而线下可达 35-40%,两者消费群体和场景不同,实际品类重合度低,对比价影响有限。 从2016年到 2023年,药 ...

Financial Data and Key Metrics Changes - The company is expected to disclose its semi-annual report on August 22, with specific performance indicators not yet available due to strict regulations from the Shanghai Stock Exchange [10] - The company anticipates growth in sales volume for its innovative drugs, particularly for products like Carrelizumab and Pemetrexed, which have recently been included in the medical insurance catalog [11][12] Business Line Data and Key Metrics Changes - The company has launched four new Class II drugs in 2024, contributing to incremental growth [13] - The focus for 2024 includes significant revenue contributions from innovative drugs such as Darsylis, Penglitan, and Levobunolol, with expectations for strong sales performance [12][13] Market Data and Key Metrics Changes - The company has observed a positive trend in market access and product inclusion in medical insurance, particularly in developed regions like Shanghai and Guangdong [6][7] - The impact of anti-corruption policies has been noted, with expectations for normalization in the future [8] Company Strategy and Development Direction - The company is focusing on expanding its innovative drug pipeline and enhancing its commercialization team to support new product launches [19][20] - There is a strategic emphasis on collaboration with international partners for licensing opportunities, with ongoing negotiations for various products [15][16] Management Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the supportive policies for the pharmaceutical industry and the potential for improved market access [5][6] - The company aims to maintain a stable sales team while enhancing the quality and expertise of its personnel to adapt to market changes [27][28] Other Important Information - The company is addressing compliance issues raised by the FDA, with corrective actions already submitted and ongoing communication to resolve any outstanding concerns [55][56] - The company is not planning to initiate new generic drug projects, focusing instead on innovative drug development [42] Q&A Session Summary Question: What potential licensing opportunities are available? - The company is actively seeking partnerships for its pipeline products, with ongoing discussions for various candidates [15][16] Question: How is the commercialization team structured for new product launches? - The team has grown to over 100 members, focusing on key products in oncology and metabolic diseases [19][20] Question: What is the current status of FDA compliance issues? - The company has submitted a comprehensive response to the FDA regarding identified deficiencies and is awaiting further inspection [55][56] Question: What are the expectations for future revenue growth? - Management indicated a target for innovative drug revenue to reach 130 billion in 2024, with a compound growth trajectory [33][34]

本次电话会议仅服务于国泰捐赠券正式签约客户会议音频及文字记录的内容仅供国泰捐赠券客户内部学习使用不得外发并且必须经国泰捐赠券研究所审核后方可留存国泰捐赠券未授权任何媒体转发此次电话会议相关内容未经允许和授权 转载转发均属侵权国泰金安证券将保留追究其法律责任的权利国泰金安证券不承担因转载转发引起的任何损失及责任市场有风险投资需谨慎提请广大投资者谨慎做出投资决策 大家好欢迎参加医药行业2024中期策略聚焦改善和创新目前所有参会者均处于静音状态现在有请主持人开始发言谢谢好的谢谢会议助理各位投资者大家晚上好欢迎大家在这个晚上的时间来参加我们医药的2024年中期的策略 那我是国军医药的分析师张拓和我一起再见了还有我们的首席丹姐我们本场的这个电话会分为两个部分第一部分是 关于中期策略聚焦改善和创新第二部分是关于定期市场上关注度比较高的院外市场的一些政策扰动以及未来的一个走势的情况现在由我先来为各位投资者汇报一下院外市场的一些最近的我们的观点后面我们首先来继续分享整体的一样的中期策略首先就是 首先就是整体医药院外市场的一个观点 好的这个是我们之前我们之前也发了另外市场的一个报告然后这边我们来做一个具体的汇报最近大家关注度比 ...

也是国内的先驱者之一今天我们非常高兴的邀请到了远大医药的高级投资者关系经理杨总来和我们进行线上的交流那首先还是请杨总用十几二十分钟的时间向大家先简单介绍一下公司的基本情况和最新的进展然后我们会留有提问的时间那我这边就先把时间交给杨总谢谢杨总 好的谢谢宋老师感谢国证证券的组织和邀请那么也非常感谢各位参会的投资者对远大医药的关注那么今天我就先把公司的整体的最新的一些近况跟大家做一下简单的分享包括公司在去年取得的业绩成绩还有我们的在经营在研发方面取得的一些进展 首先因为可能今天有些投资者对于公司不是那么的了解那么我就先整体介绍一下公司的概况远大医药是一家有80多年发展历史的一家老牌的制药企业了那么目前我们的员工是过万人包含了有境内外的实体企业超过30家 那公司是一家这个多元化这个综合性的药器我们目前的业务板块呢主要分为三大块制药然后荷药抗肿瘤及这个心脏血管精准介入器械还有一块呢就是生物 那么纵观公司的一个发展历史我们公司的前身是武汉制药厂最早的这种传统核心的产业及优势就在于心脑血管的急救领域我们是在2002年的时候并入中国远大集团2008年在香港上市之后我们就通过持续不断地扩大多元化公司的产品管线 所以就形成了我们 ...

远大240630 ...

Financial Data and Key Metrics Changes - The pharmaceutical and biotechnology sector experienced an 8.53% decline in June, with the overall market underperforming the CSI 300 index by 2.51 percentage points [22][39]. - In the fourth week of June, the sector dropped by 3.48%, with the blood products segment showing the smallest decline at 0.77% [23][26]. Business Line Data and Key Metrics Changes - The clinical trial results for domestic drugs presented at the 84th ADA conference highlighted significant weight loss effects from drugs like GZR18 and HRS9531, with GZR18 showing a weight reduction of 17.8% in the QW group after 35 weeks [29][31]. - HRS9531 demonstrated weight loss of 16.8% in the 6.0 mg group after 24 weeks, significantly outperforming the placebo group [16][29]. Market Data and Key Metrics Changes - The U.S., China, and India are identified as the countries with the highest increase in obesity patients, indicating a substantial market opportunity for weight loss medications [18][31]. - The global prevalence of obesity has increased significantly, with female obesity rates rising from 8.8% in 1990 to 18.5% in 2022 [31]. Company Strategy and Development Direction - The focus on innovative drug development for chronic health issues is evident, with companies like Innovent Biologics, Gan & Lee Pharmaceuticals, and Hengrui Medicine showcasing their advancements at the ADA conference [29][31]. - The market for weight loss drugs is expected to expand rapidly due to increasing awareness of weight management [31]. Management Comments on Operating Environment and Future Outlook - Management highlighted the promising results from recent clinical trials, suggesting a positive outlook for the adoption of new weight loss therapies in the market [29][31]. - The competitive landscape is intensifying, with multiple companies vying for market share in the obesity treatment sector [31]. Other Important Information - The report emphasizes the importance of monitoring regulatory changes and market dynamics that could impact the pharmaceutical sector's performance [41][43]. - Risk factors include potential delays in policy implementation and increased market competition [41]. Q&A Session Summary Question: What are the implications of the recent clinical trial results for GZR18? - The results indicate a strong efficacy profile for GZR18, with a significant percentage of participants achieving weight loss of 5% or more, which could lead to increased market interest and potential sales growth [29][31]. Question: How does the company plan to address the competitive landscape? - The company aims to leverage its innovative drug pipeline and strong clinical data to differentiate itself in a crowded market, focusing on patient outcomes and safety [31].

也是国内的先驱者之一今天我们非常高兴的邀请到了远大医药的高级投资者关系经理杨总来和我们进行线上的交流那首先还是请杨总用十几二十分钟的时间向大家先简单介绍一下公司的基本情况和最新的进展然后我们会留有提问的时间那我这边就先把时间交给杨总谢谢杨总 好的谢谢宋老师感谢国证证券的组织和邀请那么也非常感谢各位参会的投资者对远大医药的关注那么今天我就先把公司的整体的最新的一些近况跟大家做一下简单的分享包括公司在去年取得的业绩成绩还有我们的在经营在研发方面取得的一些进展 首先因为可能今天有些投资者对于公司不是那么的了解那么我就先整体介绍一下公司的概况远大医药是一家有80多年发展历史的一家老牌的制药企业了那么目前我们的员工是过万人包含了有境内外的实体企业超过30家 那公司是一家这个多元化这个综合性的药器我们目前的业务板块呢主要分为三大块制药然后荷药抗肿瘤及这个心脏血管精准介入器械还有一块呢就是生物 那么纵观公司的一个发展历史我们公司的前身是武汉制药厂最早的这种传统核心的产业及优势就在于心脑血管的急救领域我们是在2002年的时候并入中国远大集团2008年在香港上市之后我们就通过持续不断地扩大多元化公司的产品管线 所以就形成了我们 ...